SAM
TRDA icon

Smartleaf Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Smartleaf Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-207
Closed -$1.98K – 2968
2025
Q1 		$1.98K Sell
207
-74
-26% -$922 ﹤0.01% 2476
2024
Q4 		$4.88K Buy
281
+148
+111% +$2.68K ﹤0.01% 2254
2024
Q3 		$2.19K Buy
+133
New +$2.1K ﹤0.01% 2442

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Smartleaf Asset Management's TRDA Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 207 shares — an estimated $1.98K sold.

Smartleaf Asset Management first reported a position in TRDA in Q3 2024 and held it in 3 quarters. The position peaked at $4.88K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 207 Entrada Therapeutics shares in Q2 2025, an estimated $1.98K.
  • Smartleaf Asset Management first reported a position in Entrada Therapeutics in Q3 2024 and held it in 3 quarters.
  • Smartleaf Asset Management's Entrada Therapeutics position peaked at $4.88K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.